Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity

British Journal of Haematology

Volumn 148, Issue 6, 2010, Pages 957-961

  Voltan, Rebecca ^a   Celeghini, Claudio ^b   Melloni, Elisabetta ^a   Secchiero, Paola ^a   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Cytotoxicity; Leukaemia; Leukaemia therapy

Indexed keywords

NUTLIN 3; PERIFOSINE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PHOSPHORYLCHOLINE; PIPERAZINE DERIVATIVE;

CELL CULTURE; CELL STRAIN HL 60; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; HEMATOLOGIC DISEASE; HUMAN; LETTER; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CELL DEATH; DRUG EFFECTS; DRUG SCREENING; LEUKEMIA; PATHOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; LEUKEMIA; PHOSPHORYLCHOLINE; PIPERAZINES; TUMOR CELLS, CULTURED;

EID: 77649202972     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.08018.x     Document Type: Letter

References (8)

1. van Blitterswijk, W.J. Verheij, M. (2008) Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Current Pharmaceutical Design, 14, 2061 2074.
2. + T lymphoblastoid Jurkat cells. European Journal of Immunology, 27, 2805 2811.
3. Chou, T. Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27 55.
4. Meulmeester, E. Jochemsen, A.G. (2008) p53: a guide to apoptosis. Current Cancer Drug Targets, 8, 87 97.
5. Mitani, N., Niwa, Y. Okamoto, Y. (2007) Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Annals of Clinical Biochemistry, 44, 557 559.
6. Secchiero, P., di Iasio, M.G., Gonelli, A. Zauli, G. (2008) The MDM2 inhibitors Nutlins as an innovative therapeutic tool for the treatment of hematological malignancies. Current Pharmaceutical Design, 14, 2100 2110.
7. Vassilev, L.T. (2007) MDM2 inhibitors for cancer therapy. Trends in Molecular Medicine, 13, 23 31.
8. Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B. Hung, M.C. (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature Cell Biology, 3, 973 982.